An important limitation of C4 evaluations is that some pathological conditions, such as liver disease (cholestatic disease with hypertriglyceridemia, AST or ALT > 2× upper limit of normal) or therapy with medications able to modify BA synthesis (i.e., statins), could determine false-positive or false-negative results [106]. This evidence concerns the gene GPT and liver disorder.